Biohaven Pharmaceutical acquired by Pfizer
Pfizer agreed to acquire Biohaven Pharmaceutical, a US neurological pharmaceuticals brand, on May 10, 2022.
Transaction summary
- Target
- Biohaven Pharmaceutical
- Acquirer
- Pfizer
- Seller
- -
- Announced
- 2022-05-10
- Geography
- United States
- Type
- Acquisition
- Deal type
- Control
- Stake acquired
- -
- First added
- 2026-06-19
- Latest update
- 2026-10-21
Value and multiples
100% enterprise value
USD 12B
100% enterprise value | USD
Basis: Public source
Reported price is assumed to be 100% EV unless stated otherwise. Partial-stake estimates are qualified in the basis notes.
EV / revenue
-
Period not stated
Basis: FundComb estimate
EV / EBITDA
13.5x
EBITDA basis not stated
Basis: FundComb estimate
Amounts paid and other reported values
Original reported amounts and bases; a stake payment is distinct from the estimated whole-company valuation.
Consideration: USD 12B
Google News RSS result for Pharmaceutical Technology states Pfizer agreed to acquire Biohaven Pharmaceutical for $11.6bn in cash; full article was not fetched.
Basis
- Pharmaceutical Technology reported that Pfizer agreed to pay USD 11.6bn in cash (May 2022). The 13.5x EBITDA multiple comes from FundComb’s comps spreadsheet and is not confirmed by a public source; the EBITDA amount, period and basis behind it are not stated.
Source summary
Pfizer agrees to acquire Biohaven Pharmaceutical for $11.6bn in cash - Pharmaceutical Technology
ConfirmedContinue your research
Related transaction comps
Oyster Point Pharma acquired by Viatris
2022-11-07 · Confirmed
View transaction → biopharmaceuticalsGW Pharmaceuticals acquired by Jazz Pharmaceuticals
2021-02-03 · Confirmed
View transaction → biopharmaceuticalsAimmune Therapeutics acquired by Sociétés des Produits Nestlé S.A. / Nestlé Health Science
2020-08-31 · Estimated
View transaction → biopharmaceuticalsDermira acquired by Eli Lilly
2020-01-10 · Confirmed
View transaction →